drugset / Trial / NCT06601205
Finasteride and Flutamide in Pre-surgical Trial in Prostate Cancer.
Phase 2/3
Completed
125 enrolled
Ente Ospedaliero Ospedali Galliera
Cliniche Humanitas Gavazzeni · collabEuropean Institute of Oncology · collabUniversita degli Studi di Genova · collabUniversity of Arizona · collabUniversità Politecnica delle Marche · collab
RandomizedParallel-groupQuadruple-blindPrevention
Summary
Pre-surgical, window-of-opportunity trials provide a suitable model to assess the activity of preventive interventions in a cost-effective manner using tissue biomarkers as surrogate endpoints. Finasteride has been shown to reduce prostate cancer development in a large phase III trial, and flutamide has a well-known anticancer effect in advanced prostate cancer at the dose of 750 mg/day.
Timeline
- Start
- 2004-01-01
- Primary completion
- 2008-03-20
- Completion
- 2017-06-16
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Finasteride | Small molecule | 5 mg | — |
| Subject | flutamide | Small molecule | 250 mg | — |